Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Dolin

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|May 28, 2020
Remdesivir - An Important First StepRaphael Dolin, Martin S Hirsch
Vaccine|January 17, 2009
The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arraysJonathan S Duke-Cohan, Kristin Wollenick, Elizabeth A Witten, et al.
The Journal of Infectious Diseases|May 15, 2004
Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. 1971Raphael Dolin, Neil R Blacklow, Herbert DuPont, et al.
Vaccine|November 13, 2012
Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesStephen R Walsh, Michael S Seaman, Lauren E Grandpre, et al.
Vaccine|January 27, 2009
Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeysLauren E Grandpre, Jonathan S Duke-Cohan, Bonnie A Ewald, et al.
The Journal of Infectious Diseases|March 31, 2010
Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with DryvaxMichael S Seaman, Marissa B Wilck, Lindsey R Baden, et al.
The Journal of Infectious Diseases|March 31, 2010
Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administrationMarissa B Wilck, Michael S Seaman, Lindsey R Baden, et al.
The Journal of Infectious Diseases|September 24, 2011
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjectsLindsey R Baden, William A Blattner, Cecilia Morgan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 2, 2002
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022AKalpana Gupta, Michael Hudgens, Lawrence Corey, et al.
The Journal of Infectious Diseases|March 14, 2013
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trialStephen R Walsh, Marissa B Wilck, David J Dominguez, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|May 28, 2020
Remdesivir - An Important First StepRaphael Dolin, Martin S Hirsch
Vaccine|January 17, 2009
The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arraysJonathan S Duke-Cohan, Kristin Wollenick, Elizabeth A Witten, et al.
The Journal of Infectious Diseases|May 15, 2004
Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. 1971Raphael Dolin, Neil R Blacklow, Herbert DuPont, et al.
Vaccine|November 13, 2012
Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesStephen R Walsh, Michael S Seaman, Lauren E Grandpre, et al.
Vaccine|January 27, 2009
Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeysLauren E Grandpre, Jonathan S Duke-Cohan, Bonnie A Ewald, et al.
The Journal of Infectious Diseases|March 31, 2010
Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with DryvaxMichael S Seaman, Marissa B Wilck, Lindsey R Baden, et al.
The Journal of Infectious Diseases|March 31, 2010
Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administrationMarissa B Wilck, Michael S Seaman, Lindsey R Baden, et al.
The Journal of Infectious Diseases|September 24, 2011
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjectsLindsey R Baden, William A Blattner, Cecilia Morgan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 2, 2002
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022AKalpana Gupta, Michael Hudgens, Lawrence Corey, et al.
The Journal of Infectious Diseases|March 14, 2013
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trialStephen R Walsh, Marissa B Wilck, David J Dominguez, et al.
Pageof 3